Cancer Genetics, Inc. Will Showcase a Novel Diagnostic and Prognostic Test for Diffuse, Large B-Cell Lymphoma (DLBCL) at the American Society of Hematology Annual Meeting in New Orleans
By Italia on November 25 2013
Cancer Genetics, Inc. Will Showcase a Novel Diagnostic and Prognostic Test for Diffuse, Large B-Cell Lymphoma (DLBCL) at the American Society of Hematology Annual Meeting in New Orleans RUTHERFORD, NJ (November 25, 2013): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, is presenting data from its research collaboration with Memorial Sloan-Kettering Cancer Center (“MSKCC”) […]
Continue ReadingCancer Genetics, Inc. and Mayo Clinic Provide Update on their Joint Venture to Develop Next Generation Sequencing Company Focused on Areas of Critical Need in Oncology
By Italia on November 22 2013
RUTHERFORD, NJ (November 22, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”) is jointly hosting an event today with the Mayo Clinic announcing the first projects to be pursued by their joint venture, which is set to develop targeted diagnostic panels that leverage next generation sequencing (“NGS”). CGI and Mayo Clinic formed […]
Continue ReadingCancer Genetics, Inc. Featured in Two Key Latin American Genetics Conferences
By Italia on November 21 2013
The Company’s proprietary FHACT™ test for cervical cancer will be featured in genomic-focused workshops for leading oncologists, pathologists and cytogeneticists in Latin America RUTHERFORD, NJ (November 21, 2013): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, announces its participation in the third annual Latin American Human Genetics Congress and thirty-eighth annual National […]
Continue ReadingCancer Genetics, Inc. Announces U.S. Launch of Its Proprietary DNA-Based Cervical Cancer Diagnostic Test, FHACT™
By Italia on November 18 2013
The FHACT™ test is focused on earlier detection and enables genomic guided decision making and triaging of cervical cancer caused by HPV. CGI worked on the research and development of this test based on a multi-year research grant with the National Cancer Institute and additional validations with global partners. The test will be made available […]
Continue ReadingCancer Genetics, Inc. Announces Third Quarter Financial Results
By Jamie on November 13 2013
Test volume increased 71% year-over-year in the third quarter Revenue from commercial sales increased 67% year-over-year in the third quarter RUTHERFORD, NJ (November 13, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, reported financial results for the third quarter ended September […]
Continue ReadingCancer Genetics, Inc. Announces Conference Call to Discuss Third Quarter Results
By Italia on November 11 2013
RUTHERFORD, N.J. (November 11, 2013) — Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA-based diagnostics company focused on developing genomic-based, oncology tests and services , will hold a conference call on Wednesday, November 13, 2013, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended September 30, 2013. […]
Continue ReadingCancer Genetics to Showcase Research on its Novel, Patent-Protected, Kidney Cancer Diagnostic Array at the Association for Molecular Pathology 2013 Annual Conference
By Italia on November 9 2013
Additional presentation of multisite institutional study focused on increasing accuracy of next generation sequencing, sponsored and led by Illumina, to feature Cancer Genetics RUTHERFORD, NJ (November 07, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA-based diagnostics company focused on developing genomic-based, oncology tests and services, announced today that it will present […]
Continue ReadingCancer Genetics, Inc. Granted Patent for Kidney Cancer Diagnosis & Typing Using a Proprietary Genomic Method
By Jamie on November 6 2013
Methods in patent validated by Memorial Sloan-Kettering Cancer Center and The Cleveland Clinic RUTHERFORD, NJ (November 6, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX) (“CGI” or the “Company”), a DNA based diagnostics company focused on developing genomic-based, oncology tests and services, received a formal Notice of Allowance from the United States Patent and Trademark Office (USPTO) for […]
Continue Reading